Microbot Medical Inc. (NASDAQ:MBOT) Expected to Post Q1 2024 Earnings of ($0.17) Per Share

Microbot Medical Inc. (NASDAQ:MBOT) – Stock analysts at HC Wainwright upped their Q1 2024 earnings per share (EPS) estimates for Microbot Medical in a report released on Tuesday, April 16th. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will post earnings of ($0.17) per share for the quarter, up from their prior forecast of ($0.19). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Microbot Medical’s current full-year earnings is ($0.64) per share. HC Wainwright also issued estimates for Microbot Medical’s Q2 2024 earnings at ($0.16) EPS, Q3 2024 earnings at ($0.16) EPS, Q4 2024 earnings at ($0.13) EPS and FY2024 earnings at ($0.61) EPS.

Microbot Medical Stock Down 1.1 %

NASDAQ MBOT opened at $0.89 on Thursday. The stock has a market cap of $12.82 million, a price-to-earnings ratio of -0.82 and a beta of 1.64. Microbot Medical has a fifty-two week low of $0.86 and a fifty-two week high of $4.37. The business has a fifty day moving average of $1.20 and a 200-day moving average of $1.29.

Institutional Investors Weigh In On Microbot Medical

Hedge funds and other institutional investors have recently made changes to their positions in the business. Cetera Advisor Networks LLC purchased a new stake in shares of Microbot Medical in the first quarter valued at $78,000. Wells Fargo & Company MN grew its position in Microbot Medical by 6,713.4% during the second quarter. Wells Fargo & Company MN now owns 12,741 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 12,554 shares during the period. Renaissance Technologies LLC grew its position in Microbot Medical by 52.5% during the first quarter. Renaissance Technologies LLC now owns 15,695 shares of the biotechnology company’s stock valued at $98,000 after acquiring an additional 5,400 shares during the period. Hilltop Holdings Inc. purchased a new stake in Microbot Medical during the second quarter valued at about $52,000. Finally, Virtu Financial LLC grew its position in Microbot Medical by 75.9% during the fourth quarter. Virtu Financial LLC now owns 42,046 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 18,138 shares during the period. Hedge funds and other institutional investors own 16.30% of the company’s stock.

About Microbot Medical

Microbot Medical Inc operates as a pre-clinical medical device company in the United Kingdom. It primarily engages in the research, design, and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company also offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.